WALTHAM, Mass., May 28, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that two abstracts summarizing data from clinical trials with its vascular disrupting agent (VDA) product candidates, fosbretabulin (referred to as combretastatin A4-phosphate / CA4P) and OXi4503, will be presented in posters at the upcoming 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, May 30-June 3, 2008. Two additional abstracts containing fosbretabulin clinical trials data are published in the ASCO meeting program.
